Minerva Neurosciences | NERV - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Adma Biologics USD 64.2M 12.21M 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
AstraZeneca USD 12.22B 4.04B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cipla INR 62.31B 3.04B 2026-06
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.19M 96K 2026-03
CSL USD 5.7B 2.82B 2025-12
Eli Lilly USD 10.52B 496M 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
J&J USD 17.83B 388M 2026-06
Merck USD 15.77B 2.4B 2026-06
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 85.19B 4.91B 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sanofi EUR 9.92B 607M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12